| Systematic (IUPAC) name | |
|---|---|
| 1-(3-methyl-2-butenyl)-4-[(1R)-1-phenyl-2-(3-hydroxyphenyl)ethyl]piperazine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 83374-58-7 61311-01-1 (R) enantiomer |
| ATC code | None |
| PubChem | CID 173526 |
| ChemSpider | 26286944 |
| Synonyms | AD-1211 |
| Chemical data | |
| Formula | C23H30N2O |
| Mol. mass | 350.496 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
AD-1211 is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-prenyl-piperazine derivative, which is structurally unrelated to most other opioid drugs. The (S) enantiomers in this series are more active as opioid agonists, but the less active (R) enantiomer of this compound, AD-1211, is a mixed agonist-antagonist at opioid receptors with a similar pharmacological profile to pentazocine,[1] and has atypical opioid effects with little development of tolerance or dependence seen after extended administration in animal studies.[2][3]
| This analgesic-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)